Analyst Price Targets — ARDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 7:10 pm | Roanna Ruiz | Williams Trading | $17.00 | $5.66 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Ardelyx, Inc (ARDX) following conference |
| February 20, 2026 11:07 am | — | H.C. Wainwright | $18.00 | $6.74 | TheFly | Ardelyx price target raised to $18 from $10 at H.C. Wainwright |
| January 27, 2026 11:23 am | — | Jefferies | $15.00 | $7.80 | TheFly | Ardelyx price target raised to $15 from $8 at Jefferies |
| January 9, 2026 10:59 am | Julian Harrison | BTIG | $17.00 | $7.00 | TheFly | Ardelyx price target raised to $17 from $14 at BTIG |
| January 8, 2026 9:34 pm | — | Piper Sandler | $16.00 | $7.00 | TheFly | Ardelyx upgraded to Overweight from Neutral at Piper Sandler |
| January 8, 2026 5:46 pm | Christopher Raymond | Raymond James | $19.00 | $7.00 | TheFly | Ardelyx price target raised to $19 from $16 at Raymond James |
| November 4, 2025 2:10 pm | — | Piper Sandler | $10.00 | $5.86 | TheFly | Ardelyx price target raised to $10 from $9 at Piper Sandler |
| August 5, 2025 1:39 pm | — | Wedbush | $14.00 | $5.13 | TheFly | Ardelyx price target raised to $14 from $13 at Wedbush |
| August 5, 2025 12:40 pm | — | UBS | $12.00 | $5.13 | TheFly | Ardelyx price target raised to $12 from $11 at Raymond James |
| March 4, 2025 11:53 am | — | BTIG | $14.00 | $5.41 | TheFly | Ardelyx initiated with a Buy at BTIG |
Latest News for ARDX
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W.
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, April 30, 2026, at 4:30 p.m.
Michael Raab sold 41,666 shares of common stock for a total of approximately $243,000, with the transaction executed at around $5.84 per share on March 16, 2026. The transaction represented 2.21% of Michael Raab's aggregate and direct holdings at the time, leaving 1,816,448 shares directly owned post-sale.
WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple…
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, announced the recipients of the 2026 Derek Forfang Patient Advocate Award: Edward Drake II, Markesha Grayson, Timmy Nelson, Pesh Patel and Glenda Roberts.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARDX.
U.S. House Trading
No House trades found for ARDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.